ANL - צמיחת מכירות משנה לשנה (TTM) Adlai Nortye Ltd.

Adlai Nortye Ltd. (ANL) efficiency is based on global partnerships with oncology centers to develop targeted therapies. On GURU.Markets, the TTM revenue growth trajectory compared to last year visualizes this process, where the value 0.00 captures the metric level. Fundamentals are supported by the macroeconomic resilience of the biotech sector and the planned allocation of capital for the registration of new products.
פילוחי נתונים אנליטיים מרוכזים עבור Adlai Nortye (ANL)

Adlai Nortye Ltd. focuses on high-tech clinical development of anti-cancer drugs utilizing advanced laboratory capacities. The annual sales growth rate over a 12-month period smooths revenue volatility, revealing the true vector of business scaling. This metric measures expansion rates by comparing the current rolling window with the same period last year. Growth confirms the effectiveness of research commercialization, while a decline signals stagnation. This chart's price action determines the balance between the issuer's fundamental reliability and the risk of overpayment.